Skip to main content

Table 2 Multivariable logistic regression of risk factors for individuals with acute kidney injury compared to those without acute kidney injury by age categories (years)

From: Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16–25 years of age treated in an adult intensive care unit

Characteristic

16–25

OR (95% CI p value)

26–35

OR (95% CI p value)

36–45

OR (95% CI p value)

46–55

OR (95% CI p value)

Age per 5 years

1.39 (1.14–1.69, < 0.01)

1.21 (1.02–1.43, 0.02)

Black

1.41 (1.04–1.91, 0.02)

Other race

Diabetes

1.89 (1.09–3.29, 0.02)

1.86 (1.20–2.89, < 0.01)

1.52 (1.14–2.02, 0.01)

1.55 (1.28–1.85, 0.01)

Fluid balance > 5%

Malignancy

Hypertension

Cardiac disease

3.75 (2.23–6.29, < 0.01)

2.00 (1.47–2.72, < 0.01)

1.36 (1.12–1.64, 0.01)

Chronic kidney disease

Surgical admission

1.79 (1.44–2.23, < 0.01)

1.39 (1.14–1.71, < 0.01)

1.23 (1.05–1.72, < 0.01)

Vasopressor use

1.48 (1.04–2.12, 0.03)

1.34 (1.05–1.65, 0.01)

1.41 (1.19–1.69, < 0.01)

Mechanical ventilation

1.39 (1.09–2.12, < 0.01)

1.38 (1.16–1.31, < 0.01)

1.53 (1.33–1.73, < 0.01)

Moderate anemia

APACHE III score

1.02 (1.02–1.03, < 0.01)

1.02 (1.02–1.26, < 0.01)

1.03 (1.02–1.04, < 0.01)

1.03 (1.03–1.03, < 0.01)

eGFR

0.98 (0.98–0.99, < 0.01)

0.98 (0.98–0.99, < 0.01)

Hypotensive Index

1.13 (1.04–1.24, < 0.01)

1.04 (1.01–1.07, 0.01)

ACE inhibitor/ARB

Vancomycin

1.46 (1.00–2.13, 0.04)

1.56 (1.13–1.39, < 0.01)

1.39 (1.08–1.77, 0.01)

1.45 (1.18–1.77, < 0.01)

Other antibiotics

Calcineurin inhibitor

2.72 (1.45–5.12, < 0.01)

2.45 (1.59–3.75, < 0.01)

NSAID

0.51 (0.32–0.82, < 0.01)

0.68 (0.49–0.80, 0.02)

0.78 (0.63–0.96, 0.01)

0.92 (0.80–1.07, 0.03)

Other nephrotoxic medications

1.60 (1.03–2.49, 0.03)

 

AUC (Q1–Q3)

0.754 (0.732–0.776)

0.769 (0.749–0.789)

0.772 (0.757–0.787)

0.770 (0.758–0.781)

  1. OR odds ratio, CI confidence interval, APACHE Acute Physiology and Chronic Healthy Evaluation, eGFR estimated glomerular filtration rate, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, NSAID nonsteroidal anti-inflammatory drug, ROC receiver operator curve